ID: ALA5288802

Max Phase: Preclinical

Molecular Formula: C7H4BrN3O4S

Molecular Weight: 306.10

Associated Items:

Representations

Canonical SMILES:  O=[N+]([O-])c1cc(Br)cc2c1NC=NS2(=O)=O

Standard InChI:  InChI=1S/C7H4BrN3O4S/c8-4-1-5(11(12)13)7-6(2-4)16(14,15)10-3-9-7/h1-3H,(H,9,10)

Standard InChI Key:  DTWMSFNRYJPFLA-UHFFFAOYSA-N

Associated Targets(Human)

Aldose reductase 1404 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 306.10Molecular Weight (Monoisotopic): 304.9106AlogP: 1.50#Rotatable Bonds: 1
Polar Surface Area: 101.67Molecular Species: NEUTRALHBA: 5HBD: 1
#RO5 Violations: 0HBA (Lipinski): 7HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 12.99CX Basic pKa: CX LogP: 1.71CX LogD: 1.71
Aromatic Rings: 1Heavy Atoms: 16QED Weighted: 0.63Np Likeness Score: -1.13

References

1. Kousaxidis A, Petrou A, Lavrentaki V, Fesatidou M, Nicolaou I, Geronikaki A..  (2020)  Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus.,  207  [PMID:32871344] [10.1016/j.ejmech.2020.112742]

Source